French laboratories form cancer diagnostics alliance
This article was originally published in Clinica
Executive Summary
French drug discovery company ExonHit Therapeutics and diagnostics company bioMerieux-Pierre Fabre have entered a five-year deal to develop ExonHit's Proof-Hit breast and colon cancer diagnostic tool. The companies, both Paris-based, say that combining their respective expertise will provide new cancer therapeutics and develop the required diagnostics to devise and apply personalised medicines.